Scinai Immunotherapeutics Ltd.
SCNI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001611747
No open-market purchases or sales by Scinai Immunotherapeutics Ltd. insiders were filed in the last 90 days; 11 institutions reported holding it in 13F filings for Q2 2026, worth $49.1K in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Scinai Immunotherapeutics Ltd. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 13 | 9 | −4 |
| SharesConverted for a 1-for-10 split | 41.0K | 19.6K | −21.4K (−52.1%) |
| Value | $212.7K | $54.7K | −$158.0K (−74.3%) |
New holders (1)
Institutions that held Scinai Immunotherapeutics Ltd. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Bank of America Corp | 100 | $278 | 0.00% |
Sold out (5)
Institutions that held Scinai Immunotherapeutics Ltd. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Armistice Capital, LLC | 121,785 | $63.2K |
| Citadel Advisors LLC | 12,214 | $6.31K |
| Millennium Management LLC | 10,613 | $5.48K |
| Qube Research & Technologies Ltd | 7 | $4 |
| Royal Bank of Canada | 4 | $0 |